Companies in #Systemic Lupus Erythematosus
Found 2 companies operating in this sector.
Cullinan Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases and cancer. Its clinical-stage portfolio includes CLN-978, a wholly owned CD19xCD3 bispecific T cell engager being studied as an off-the-shelf subcutaneous therapy for rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease, and zipalertinib, a brain-penetrant EGFR exon 20 insertion inhibitor developed in partnership with Taiho Oncology for non-small cell lung cancer that reported positive Phase 3 REZILIENT3 results in September 2026. The company was founded in 2016, listed on Nasdaq in January 2021, and is led by President and Chief Executive Officer Nadim Ahmed.
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead candidate, EB103, is in a Phase I/II clinical trial for diffuse large B-cell lymphoma, and the company is advancing EB104 preclinically for diffuse large B-cell lymphoma and acute lymphocytic leukemia and EB201 preclinically for systemic lupus erythematosus. The company's ARTEMIS cell receptor platform is designed to develop and commercialize T-cell therapies targeting CD19 and CD22 for hematologic malignancies, and it has a collaboration with Eureka Therapeutics and Imugene covering solid-tumor treatments that combine Imugene's CF33-CD19t with EB103. Estrella Immunopharma is a subsidiary of Eureka Therapeutics and is headquartered in Emeryville, California. The company trades on the Nasdaq Capital Market, where it disclosed on September 1, 2026 that it had received a notification of non-compliance with continued listing standards, and it has until March 1, 2027 to restore its market value of listed securities above $35 million for at least ten consecutive days.